Bilirubin has potent biological beneficial effects, protecting against atherosclerosis, obesity, and metabolic syndrome. The aim of this study was to assess serum bilirubin concentrations and (TA)n and (GT)n microsatellite variations in the promoter regions of the UGT1A1 and HMOX1 genes, respectively, in patients with type 2 diabetes mellitus (T2DM). The study was carried out in 220 patients with T2DM and 231 healthy control subjects, in whom standard biochemical tests were performed. The (TA)n and (GT)n dinucleotide variations were determined by means of fragment (size-based) analysis using an automated capillary DNA sequencer. Compared to controls, both male and female patients with T2DM had lower serum bilirubin concentrations (9.9 vs. 12.9 μmol/L, and 9.0 vs. 10.6 μmol/L, in men and women, respectively, p < 0.001). Phenotypic Gilbert syndrome was much less prevalent in T2DM patients, as was the frequency of the (TA)7/7UGT1A1 genotype in male T2DM patients. (GT)nHMOX1 genetic variations did not differ between diabetic patients and controls. Our results demonstrate that the manifestation of T2DM is associated with lower serum bilirubin concentrations. Consumption of bilirubin due to increased oxidative stress associated with T2DM seems to be the main explanation, although (TA)n repeat variations in UGT1A1 partially contribute to this phenomenon.

3rd Department of Internal Medicine 1st Faculty of Medicine Charles University General University Hospital Prague Katerinska 32 12000 Prague Czech Republic

4th Department of Internal Medicine 1st Faculty of Medicine Charles University General University Hospital Prague Katerinska 32 12000 Prague Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University General University Hospital Prague Katerinska 32 12000 Prague Czech Republic

Zobrazit více v PubMed

Vitek L., Schwertner H.A. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv. Clin. Chem. 2007;43:1–57. doi: 10.1016/s0065-2423(06)43001-8. PubMed DOI

Vitek L., Hinds T.D., Jr., Stec D.E., Tiribelli C. The physiology of bilirubin: Health and disease equilibrium. Trends Mol. Med. 2023;29:315–328. doi: 10.1016/j.molmed.2023.01.007. PubMed DOI PMC

Vitek L., Tiribelli C. Bilirubin: The yellow hormone? J. Hepatol. 2021;75:1485–1490. doi: 10.1016/j.jhep.2021.06.010. PubMed DOI

Vitek L. Bilirubin as a signaling molecule. Med. Res. Rev. 2020;40:1335–1351. doi: 10.1002/med.21660. PubMed DOI

Vitek L., Jirsa M., Brodanova M., Kalab M., Marecek Z., Danzig V., Novotny L., Kotal P. Gilbert syndrome and ischemic heart disease: A protective effect of elevated bilirubin levels. Atherosclerosis. 2002;160:449–456. doi: 10.1016/S0021-9150(01)00601-3. PubMed DOI

Novotny L., Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: A meta-analysis of published studies. Exp. Biol. Med. 2003;228:568–571. doi: 10.1177/15353702-0322805-29. PubMed DOI

Jenko-Praznikar Z., Petelin A., Jurdana M., Ziberna L. Serum bilirubin levels are lower in overweight asymptomatic middle-aged adults: An early indicator of metabolic syndrome? Metabolism. 2013;62:976–985. doi: 10.1016/j.metabol.2013.01.011. PubMed DOI

Ziberna L., Jenko-Praznikar Z., Petelin A. Serum bilirubin levels in overweight and obese individuals: The importance of anti-inflammatory and antioxidant responses. Antioxidants. 2021;10:1352. doi: 10.3390/antiox10091352. PubMed DOI PMC

Wu Y., Li M., Xu M., Bi Y., Li X., Chen Y., Ning G., Wang W. Low serum total bilirubin concentrations are associated with increased prevalence of metabolic syndrome in Chinese. J. Diabetes. 2011;3:217–224. doi: 10.1111/j.1753-0407.2011.00138.x. PubMed DOI

Ko G.T., Chan J.C., Woo J., Lau E., Yeung V.T., Chow C.C., Li J.K., So W.Y., Cockram C.S. Serum bilirubin and cardiovascular risk factors in a Chinese population. J. Cardiovasc. Risk. 1996;3:459–463. doi: 10.1177/174182679600300508. PubMed DOI

Vitek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front. Pharmacol. 2012;3:55. doi: 10.3389/fphar.2012.00055. PubMed DOI PMC

Wei Y., Liu C., Lai F., Dong S., Chen H., Chen L., Shi L., Zhu F., Zhang C., Lv X., et al. Associations between serum total bilirubin, obesity and type 2 diabetes. Diabetol. Metab. Syndr. 2021;13:143. doi: 10.1186/s13098-021-00762-0. PubMed DOI PMC

Jin C.H., Wang J.W., Ke J.F., Li J.B., Li M.F., Li L.X. Low-normal serum unconjugated bilirubin levels are associated with late but not early carotid atherosclerotic lesions in T2DM subjects. Front. Endocrinol. 2022;13:948338. doi: 10.3389/fendo.2022.948338. PubMed DOI PMC

Fu J., Wang Q., Zhang L., Liu J., Wang G. Serum Bilirubin Level Is Increased in Metabolically Healthy Obesity. Front. Endocrinol. 2022;12:1808. doi: 10.3389/fendo.2021.792795. PubMed DOI PMC

Alouffi S. Serum bilirubin levels are negatively associated with atherogenic lipids in Saudi subjects with type 2 diabetes: A pilot study. Electron. J. Gen. Med. 2023;20:em444. doi: 10.29333/ejgm/12777. DOI

Zhang F., Guan W., Fu Z., Zhou L., Guo W., Ma Y., Gong Y., Jiang W., Liang H., Zhou H. Relationship between serum indirect bilirubin level and insulin sensitivity: Results from two independent cohorts of obese patients with impaired glucose regulation and type 2 diabetes mellitus in China. Int. J. Endocrinol. 2020;2020:5681296. doi: 10.1155/2020/5681296. PubMed DOI PMC

Yao Q., Jiang X., Kou L., Samuriwo A.T., Xu H.L., Zhao Y.Z. Pharmacological actions and therapeutic potentials of bilirubin in islet transplantation for the treatment of diabetes. Pharmacol. Res. 2019;145:104256. doi: 10.1016/j.phrs.2019.104256. PubMed DOI

Inoguchi T., Sasaki S., Kobayashi K., Takayanagi R., Yamada T. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. J. Am. Med. Assoc. 2007;298:1398–1400. doi: 10.1001/jama.298.12.1398-b. PubMed DOI

Bosma P.J., Chowdhury J.R., Bakker C., Gantla S., de Boer A., Oostra B.A., Lindhout D., Tytgat G.N., Jansen P.L., Oude Elferink R.P., et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N. Engl. J. Med. 1995;333:1171–1175. doi: 10.1056/NEJM199511023331802. PubMed DOI

Vitek L., Novotny L., Zak A., Stankova B., Zima T., Polito A., Cesare G., Zerbinati C., Iuliano L. Relationship between serum bilirubin and uric acid to oxidative stress markers in Italian and Czech populations. J. Appl. Biomed. 2013;11:209–221. doi: 10.2478/v10136-012-0030-y. DOI

Wagner K.H., Khoei N.S., Hana C.A., Doberer D., Marculescu R., Bulmer A.C., Hormann-Wallner M., Molzer C. Oxidative stress and related biomarkers in Gilbert’s syndrome: A secondary analysis of two case-control studies. Antioxidants. 2021;10:1474. doi: 10.3390/antiox10091474. PubMed DOI PMC

Lin J.P., Vitek L., Schwertner H.A. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin. Chem. 2010;56:1535–1543. doi: 10.1373/clinchem.2010.151043. PubMed DOI

Exner M., Minar E., Wagner O., Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic. Biol. Med. 2004;37:1097–1104. doi: 10.1016/j.freeradbiomed.2004.07.008. PubMed DOI

Schwertner H.A., Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: Possible protective effects and therapeutic applications of bilirubin. Atherosclerosis. 2008;198:1–11. doi: 10.1016/j.atherosclerosis.2008.01.001. PubMed DOI

Bao W., Song F.F., Li X.Y., Rong S.A., Yang W., Wang D., Xu J.Q., Fu J.A., Zhao Y.T., Liu L.G. Association between heme oxygenase-1 gene promoter polymorphisms and type 2 diabetes mellitus: A HuGE review and meta-analysis. Am. J. Epidemiol. 2010;172:631–636. doi: 10.1093/aje/kwq162. PubMed DOI

Lee E.Y., Lee Y.H., Kim S.H., Chung K.S., Kwon O., Kim B.S., Nam C.M., Park C.S., Lee B.W., Kang E.S., et al. Association between heme oxygenase-1 promoter polymorphisms and the development of albuminuria in type 2 diabetes: A case-control study. Medicine. 2015;94:e1825. doi: 10.1097/MD.0000000000001825. PubMed DOI PMC

Chen Y.H., Chau L.Y., Chen J.W., Lin S.J. Serum bilirubin and ferritin levels link between heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care. 2008;31:1615–1620. doi: 10.2337/dc07-2126. PubMed DOI PMC

Eremiasova L., Hubacek J.A., Danzig V., Adamkova V., Mrazova L., Pitha J., Lanska V., Cifkova R., Vitek L. Serum bilirubin in the Czech population—Relationship to the risk of myocardial infarction in males. Circ. J. 2020;84:1779–1785. doi: 10.1253/circj.CJ-20-0192. PubMed DOI

Vitek L. Bilirubin and atherosclerotic diseases. Physiol. Res. 2017;66:S11–S20. doi: 10.33549/physiolres.933581. PubMed DOI

Choi S.H., Yun K.E., Choi H.J. Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults. Nutr. Metab. Cardiovasc. Dis. 2013;23:31–37. doi: 10.1016/j.numecd.2011.03.001. PubMed DOI

Petrtyl J., Dvorak K., Stritesky J., Lenicek M., Jiraskova A., Smid V., Haluzik M., Bruha R., Vitek L. Association of serum bilirubin and functional variants of heme oxygenase 1 and bilirubin UDP-glucuronosyl transferase genes in Czech adult patients with non-alcoholic fatty liver disease. Antioxidants. 2021;10:2000. doi: 10.3390/antiox10122000. PubMed DOI PMC

Wagner K.H., Wallner M., Molzer C., Gazzin S., Bulmer A.C., Tiribelli C., Vitek L. Looking to the horizon: The role of bilirubin in the development and prevention of age-related chronic diseases. Clin. Sci. 2015;129:1–25. doi: 10.1042/CS20140566. PubMed DOI

Stec D.E., John K., Trabbic C.J., Luniwal A., Hankins M.W., Baum J., Hinds T.D., Jr. Bilirubin binding to PPARalpha inhibits lipid accumulation. PLoS ONE. 2016;11:e0153427. doi: 10.1371/journal.pone.0153427. PubMed DOI PMC

Molzer C., Wallner M., Kern C., Tosevska A., Schwarz U., Zadnikar R., Doberer D., Marculescu R., Wagner K.H. Features of an altered AMPK metabolic pathway in Gilbert’s syndrome, and its role in metabolic health. Sci. Rep. 2016;6:30051. doi: 10.1038/srep30051. PubMed DOI PMC

Gordon D.M., Blomquist T.M., Miruzzi S.A., McCullumsmith R., Stec D.E., Hinds T.D., Jr. RNA sequencing in human HepG2 hepatocytes reveals PPAR-alpha mediates transcriptome responsiveness of bilirubin. Physiol. Genom. 2019;51:234–240. doi: 10.1152/physiolgenomics.00028.2019. PubMed DOI PMC

Fu Y.Y., Kang K.J., Ahn J.M., Kim H.R., Na K.Y., Chae D.W., Kim S., Chin H.J. Hyperbilirubinemia reduces the streptozotocin-induced pancreatic damage through attenuating the oxidative stress in the Gunn rat. Tohoku J. Exp. Med. 2010;222:265–273. doi: 10.1620/tjem.222.265. PubMed DOI

Zucker S.D., Horn P.S., Sherman K.E. Serum bilirubin levels in the US population: Gender effect and inverse correlation with colorectal cancer. Hepatology. 2004;40:827–835. doi: 10.1002/hep.1840400412. PubMed DOI

Jiraskova A., Bortolussi G., Dostalova G., Eremiasova L., Golan L., Danzig V., Linhart A., Vitek L. Serum bilirubin levels and promoter variations in HMOX1 and UGT1A1 genes in patients with Fabry disease. Oxid. Med. Cell Long. 2017;2017:9478946. doi: 10.1155/2017/9478946. PubMed DOI PMC

Jiraskova A., Lenicek M., Vitek L. Simultaneous genotyping of microsatellite variations in HMOX1 and UGT1A1 genes using multicolored capillary electrophoresis. Clin. Biochem. 2010;43:697–699. doi: 10.1016/j.clinbiochem.2010.01.006. PubMed DOI

Vitek L., Bellarosa C., Tiribelli C. Induction of mild hyperbilirubinemia: Hype or real therapeutic opportunity? Clin. Pharmacol. Ther. 2019;106:568–575. doi: 10.1002/cpt.1341. PubMed DOI